Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
Francesco Maura(Memorial Sloan Kettering Cancer Center), Kenneth H. Shain(Moffitt Cancer Center), Etta Rozen Füller(Dana-Farber Cancer Institute), P. Leif Bergsagel(Mayo Clinic in Arizona), Kylee Maclachlan(Memorial Sloan Kettering Cancer Center), Issam S. Hamadeh(Memorial Sloan Kettering Cancer Center), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Xiaohong Zhao(Moffitt Cancer Center), Praneeth Sudalagunta(Moffitt Cancer Center), José A. Martinez‐Climent(Marqués de Valdecilla University Hospital), Mark B. Meads(Moffitt Cancer Center), Marta Larráyoz(Clinica Universidad de Navarra), Patrick R. Hagner(Bristol-Myers Squibb (United States)), Erin W. Meermeier(Oregon Health & Science University), Frederick L. Locke(Moffitt Cancer Center), Sungwoo Ahn(University of Calgary), Holly Lee(University of Calgary), Bachisio Ziccheddu(University of Miami Health System), Edward L. Briercheck(The Ohio State University), Jamie K. Teer(University of Virginia), Noémie Leblay(University of Calgary), Eric L. Smith(New England Baptist Hospital), Anusuya Ramasubramanian(Dana-Farber Cancer Institute), Sham Mailankody(Memorial Sloan Kettering Cancer Center), Ciara L. Freeman(Moffitt Cancer Center), Marios Papadimitriou(Sylvester Comprehensive Cancer Center), Phaedra Agius(New York Genome Center), Paola Neri(University of Calgary), Nizar J. Bahlis(Institute of Cancer Research), Meaghen E. Sharik(Mayo Clinic in Arizona), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Ariosto Siqueira Silva(Moffitt Cancer Center), Michael Durante(University of Miami Health System), Juan-José Garcés(Memorial Sloan Kettering Cancer Center), Rachid Baz(Moffitt Cancer Center), Tomáš Jelı́nek(University Hospital Ostrava), Meghan Menges(Moffitt Cancer Center), Marta Chesi(Mayo Clinic in Arizona), Megan T. Du(Mayo Clinic in Arizona), Ola Landgren(University of Miami Health System), Melissa Alsina(Moffitt Cancer Center), Ross Firestone(Memorial Sloan Kettering Cancer Center), Xiaofei Song(Jiangsu University), Benjamin Diamond(Memorial Sloan Kettering Cancer Center), Doris K. Hansen(Moffitt Cancer Center), Kayla Reid(Moffitt Cancer Center)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k